Home Noxopharm Limited (ASX: NOX)

Noxopharm Limited (ASX: NOX)

    Noxopharm pre-clinical evidence confirms Veyonda® abscopal effect; NOX completes three years on ASX

    On 21 August 2019, clinical-stage drug development company Noxopharm Limited (ASX: NOX) pre-clinical evidence confirmed that its lead drug candidate Veyonda® has the potential...

    A Lens On Noxopharm’s June 2019 Quarterly Results

    Noxopharm Limited (ASX: NOX) has recently released its quarterly report for the three months ended 30 June 2019, covering updates from both Noxopharm and...

    Noxopharm secures AU$26 million funding facility to ramp up the development of Veyonda®

    Noxopharm Limited (ASX: NOX) plans to accelerate the development of Veyonda® on the foundation of its encouraging interim results from both its DARRT-1 and...

    Noxopharm Eyes The Development Of A Well-Tolerated ‘STING agonist’ Drug

    Noxopharm Limited (ASX: NOX) has released July 2019 edition of its Newsletter called 'Versatility'. The clinical-stage drug development company, Noxopharm reports on the progress of...

    Recent News